# Pietro A. Canetta

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pietro-a-canetta/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,057 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 41 |
| i10-index | 76 |
| Last Known Institution | Columbia University Irving Medical Center |
| OpenAlex ID | https://openalex.org/A5014244661 |
| ORCID iD | 0000-0003-1130-5486 |
| Works | 156 |

## Researcher papers

- [Diagnostic Utility of Exome Sequencing for Kidney Disease](https://scholariq.org/papers/diagnostic-utility-of-exome-sequencing-for-kidney-disease/)
- [Sensitivity and Specificity of a Single Emergency Department Measurement of Urinary Neutrophil Gelatinase–Associated Lipocalin for Diagnosing Acute Kidney Injury](https://scholariq.org/papers/sensitivity-and-specificity-of-a-single-emergency-department-measurement-of/)
- [An atlas of healthy and injured cell states and niches in the human kidney](https://scholariq.org/papers/an-atlas-of-healthy-and-injured-cell-states-and-niches-in-the-human-kidney/)
- [Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy](https://scholariq.org/papers/rituximab-or-cyclosporine-in-the-treatment-of-membranous-nephropathy/)
- [Kidney Biopsy Findings in Patients with COVID-19](https://scholariq.org/papers/kidney-biopsy-findings-in-patients-with-covid-19/)
- [Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis](https://scholariq.org/papers/eculizumab-for-dense-deposit-disease-and-c3-glomerulonephritis/)
- [Diagnostic and Prognostic Stratification in the Emergency Department Using Urinary Biomarkers of Nephron Damage](https://scholariq.org/papers/diagnostic-and-prognostic-stratification-in-the-emergency-department-using/)
- [A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction](https://scholariq.org/papers/a-randomized-controlled-trial-of-rituximab-in-iga-nephropathy-with-proteinuria/)
- [Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga/)
- [Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection](https://scholariq.org/papers/acute-kidney-injury-due-to-collapsing-glomerulopathy-following-covid-19/)
- [Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy](https://scholariq.org/papers/mycophenolate-mofetil-in-combination-with-steroids-for-treatment-of-c3/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)

## Researcher university

- [Columbia University Irving Medical Center](https://scholariq.org/institutions/columbia-university-irving-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.